ABOUT THIS EVENT

Neuronetics, Inc. (Nasdaq: STIM), a commercial-stage medical technology company focused on developing products that improve the quality of life for patients who suffer from psychiatric disorders, visited the Nasdaq MarketSite in Times Square.

Chris Thatcher, Neuronetics President & CEO, rang the Closing Bell as part of the company’s efforts to raise awareness of depression and the importance and accessibility of treatment options during National Depression Awareness Month in October. Thatcher was joined by several patient advocates who achieved remission from their depression and by leading mental health organizations, including Clinical TMS Society and Mental Health America.

In his remarks, Thatcher focused on the value of the company’s NeuroStar Advanced Therapy system as a safe and proven non-drug treatment option for the 5.5 million adult patients in the U.S. with Major Depressive Disorder (MDD) who do not benefit from antidepressant medications.

NeuroStar Advanced Therapy was the first TMS device to receive FDA clearance in 2008, and since that time, has been utilized in more than 2.5 million treatments worldwide.